摘要
炎症性肠病(inflammatory bowel disease,IBD)是一种慢性易复发的炎症性疾病,主要包括溃疡性结肠炎(ulcerative colitis,UC)和克罗恩病(Crohn’s disease,CD)。近年来IBD在我国的发病率逐年上升趋势明显,已成为消化系统的常见病。IBD的发病机制尚不清楚,目前世界上还没有能够彻底治愈IBD的药物。相比于单克隆抗体类药物,小分子药物具有生产成本低、容易制成口服制剂、不存在免疫原性等优势。本综述归纳总结了近年来IBD小分子免疫抑制剂的研发进展情况。
Inflammatory bowel disease（IBD） is a chronic relapsing inflammatory disorder including mainly ulcerative colitis（UC） and Crohn＇s disease（CD）.In China,IBD has become a common disease of the digestive system with an dramatic increase in incidence in recent years.The pathogenesis of IBD is not yet clear,and no drugs can completely cure IBD.Compared with monoclonal antibody drugs,small molecule drugs have the advantages of low cost,easy development as oral agents,and absence of immunogenicity.This review summarizes the recent research and development of small molecule immunosuppressants for IBD.
作者
李美
苗建壮
许述
LI Mei;MIAO Jian-zhuang;XU Shu(State Key Laboratory of Bioactive Substance and Function of Natural Medicines,Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100050,China)
出处
《药学学报》
CAS
CSCD
北大核心
2018年第8期1289-1301,共13页
Acta Pharmaceutica Sinica
基金
国家自然科学基金资助项目(21502234,21672262)
中国医学科学院医学与健康科技创新工程经费资助项目(2016-I2M-3-009)
关键词
炎症性肠病
溃疡性结肠炎
克罗恩病
免疫抑制剂
小分子药物
inflammatory bowel disease
ulcerative colitis
Crohn＇s disease
immunosuppressant
smallmolecule drug
